• Something wrong with this record ?

Types of second primary cancer influence overall survival in cutaneous melanoma

G. Zheng, S. Chattopadhyay, K. Sundquist, J. Sundquist, A. Försti, A. Hemminki, K. Hemminki

. 2021 ; 21 (1) : 1123. [pub] 20211019

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22012080

BACKGROUND: Favorable survival in malignant cutaneous melanoma (melanoma) has increased the likelihood of second primary cancer (SPC). We assess the influence of patient characteristics at diagnosis of first melanoma and the type of SPC (second melanoma and other SPC) on overall survival. METHODS: We used the Swedish Cancer Registry data to assess overall survival in melanoma for the period 1990 to 2015. Kaplan-Meier curves were plotted and hazard ratios (HRs) were estimated with Cox regression models by considering SPC diagnosis as a time-dependent variable. RESULTS: A total of 46,726 patients were diagnosed with melanoma, and 15.3% of them developed SPC, among which, two thirds were other SPCs. Second melanomas were diagnosed early (31% during the first year) compared to non-melanoma SPCs (9.5%). Survival for women with second melanoma or other SPC (56 and 21% alive after 25 years of follow-up, respectively) exceeded the male rates (21 and 10%, respectively) but all these figures were lower than for females (60% alive) or males (48%) without SPC. Time dependent analysis showed vastly increased HRs for cancer types that are fatal also as first cancers, but SPC-specific HRs remained relatively uniform, irrespective of SPC diagnosed soon or late after first melanoma. In early-onset melanoma, SPC diagnosis after 10 years may not negatively influence overall survival. CONCLUSIONS: As the overall survival of patients with many types of SPCs is unfavorable, advice about health lifestyle should benefit smoking patients and early detection methods may be recommended for SPCs of the breast, prostate and colorectum.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012080
003      
CZ-PrNML
005      
20220506130415.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-021-08845-x $2 doi
035    __
$a (PubMed)34663263
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Zheng, Guoqiao $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden
245    10
$a Types of second primary cancer influence overall survival in cutaneous melanoma / $c G. Zheng, S. Chattopadhyay, K. Sundquist, J. Sundquist, A. Försti, A. Hemminki, K. Hemminki
520    9_
$a BACKGROUND: Favorable survival in malignant cutaneous melanoma (melanoma) has increased the likelihood of second primary cancer (SPC). We assess the influence of patient characteristics at diagnosis of first melanoma and the type of SPC (second melanoma and other SPC) on overall survival. METHODS: We used the Swedish Cancer Registry data to assess overall survival in melanoma for the period 1990 to 2015. Kaplan-Meier curves were plotted and hazard ratios (HRs) were estimated with Cox regression models by considering SPC diagnosis as a time-dependent variable. RESULTS: A total of 46,726 patients were diagnosed with melanoma, and 15.3% of them developed SPC, among which, two thirds were other SPCs. Second melanomas were diagnosed early (31% during the first year) compared to non-melanoma SPCs (9.5%). Survival for women with second melanoma or other SPC (56 and 21% alive after 25 years of follow-up, respectively) exceeded the male rates (21 and 10%, respectively) but all these figures were lower than for females (60% alive) or males (48%) without SPC. Time dependent analysis showed vastly increased HRs for cancer types that are fatal also as first cancers, but SPC-specific HRs remained relatively uniform, irrespective of SPC diagnosed soon or late after first melanoma. In early-onset melanoma, SPC diagnosis after 10 years may not negatively influence overall survival. CONCLUSIONS: As the overall survival of patients with many types of SPCs is unfavorable, advice about health lifestyle should benefit smoking patients and early detection methods may be recommended for SPCs of the breast, prostate and colorectum.
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a přežívající onkologičtí pacienti $x statistika a číselné údaje $7 D000073116
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x mortalita $7 D008545
650    _2
$a lidé středního věku $7 D008875
650    _2
$a sekundární malignity $x mortalita $7 D016609
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a registrace $7 D012042
650    _2
$a sexuální faktory $7 D012737
650    _2
$a nádory kůže $x mortalita $7 D012878
650    _2
$a kouření $7 D012907
650    _2
$a časové faktory $7 D013997
651    _2
$a Švédsko $x epidemiologie $7 D013548
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chattopadhyay, Subhayan $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany
700    1_
$a Sundquist, Kristina $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA $u Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Matsue, Japan
700    1_
$a Sundquist, Jan $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA $u Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Matsue, Japan
700    1_
$a Försti, Asta $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden $u Hopp Children's Cancer Center (KiTZ), 69120, Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Hemminki, Kari $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. K.Hemminki@dkfz.de $u Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden. K.Hemminki@dkfz.de $u Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic. K.Hemminki@dkfz.de $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. K.Hemminki@dkfz.de
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 21, č. 1 (2021), s. 1123
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34663263 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130407 $b ABA008
999    __
$a ok $b bmc $g 1789605 $s 1163281
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 1 $d 1123 $e 20211019 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options